Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MNPR-101-PCTA-177Lu in Solid Tumors
NCT06617169Phase 1Active, not recruiting
- Sponsor
- Monopar Therapeutics Inc.
- Start
- Oct 2024
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of MNPR-101-PCTA-177Lu in solid tumor, bladder cancer, urothelial carcinoma (UC) and 6 more (5 arms), sponsored by Monopar Therapeutics Inc. Primary endpoints: Dose-Limiting Toxicities at 6 weeks and Treatment-Emergent Adverse Events at 24 weeks. Started Oct 2024; status: active, not recruiting.
02
Drugs
MNPR-101-PCTA-177Lu
03
Conditions
solid tumorbladder cancerurothelial carcinoma (UC)triple-negative breast cancer (TNBC)lung cancer
Beyond the preview
Go deeper on NCT06617169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06617169.